Abstract
Abstract Arotinolol and its main metabolite, AC 623, both antihypertensive agents with β blocking properties were simultaneously determined in human plasma and urine, using solid-liquid extraction and reversed phase HPLC with fluorimetric detection; U. V. detection could be added as a further control of the specificity of the method. Extraction yields were satisfactory and stable. Calibration curves in plasma of 0 to 100 ng/ml Arotinolol and 0 to 10 ng/ml AC 623 were used; in urine concentrations of 0 to 1000 ng/ml of both drugs were quantified. Concentrations of 2 ng/ml Arotinolol and 1 ng/ml AC 623 in plasma and of 20 ng/ml of both drugs in urine could be quantified with good accuracy. Repeatability (intra-day; n = 6) was studied at 3 concentrations covering the standard curve ranges. Reproducibility was estimated from calibration curves (10 in plasma and in urine) carried out during a pharmacokinetic study in man. Specificity was verified in general and with regards to another metabolite present in man. The method is shown to be well adapted for accurate determination of Arotinolol and its main metabolite in biological samples during pharmacokinetic and clinical studies.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
